Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1505-1513

  Marks, Morgan ^a   Gravitt, Patti E ^a   Gupta, Swati B ^b   Liaw, Kai Li ^b   Tadesse, Amha ^b   Kim, Esther ^a   Phongnarisorn, Chailert ^c   Wootipoom, Virach ^d   Yuenyao, Pissimai ^e   Vipupinyo, Charoen ^f   Sriplienchan, Somchai ^g   Celentano, David D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f RAJAVITHI HOSPITAL   (Thailand)

^g Research Institute for Health Sciences   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

ADULT; AGE; CERVICAL ECTOPY; COHORT ANALYSIS; CONFERENCE PAPER; DRUG USE; FEMALE; GEOGRAPHY; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL BEHAVIOR; THAILAND; TREATMENT DURATION; UTERINE CERVIX; VAGINITIS; VIRAL CLEARANCE; VIRUS DETECTION;

ADULT; ALPHAPAPILLOMAVIRUS; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; DNA PROBES, HPV; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION, SPONTANEOUS; RISK FACTORS; VAGINAL SMEARS;

EID: 80054732065     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir560     Document Type: Conference Paper

References (33)

1. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-21.
2. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet 2002; 359:1085-92. (Pubitemid 34270731)
3. Chen YH, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 1996; 224:651-9.
4. Kim CJ, Um SJ, Kim TY, et al. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer 2000; 10:157-64. (Pubitemid 30351316)
5. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989; 70:2227-32. (Pubitemid 19215129)
6. Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993; 81:5-12. (Pubitemid 23041694)
7. Pater MM, Mittal R, Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 1994; 2:229-34.
8. Ruutu M, Wahlroos N, Syrjanen K, Johansson B, Syrjanen S. Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 2006; 16:1261-8. (Pubitemid 43886755)
9. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA 2005; 102: 2490-5. (Pubitemid 40279404)
10. Lambert KC, Curran EM, Judy BM, Milligan GN, Lubahn DB, Estes DM. Estrogen receptor alpha (ERalpha) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17beta-estradiol acts through ERalpha to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. J Immunol 2005; 175:5716-23. (Pubitemid 41508054)
11. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007; 67:1626-35. (Pubitemid 46383388)
12. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 2008; 68:9928-34.
13. Marks M, Gravitt PE, Gupta SB, et al. The association of hormonal contraceptive use and HPV prevalence. Int J Cancer 2010; 128:2962-70.
14. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95. (Pubitemid 44912541)
15. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22. (Pubitemid 13221599)
16. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
17. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61. (Pubitemid 30043317)
18. Coutlee F, Gravitt P, Kornegay J, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002; 40:902-7. (Pubitemid 34208642)
19. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1:HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3):S1-S10. (Pubitemid 44293019)
20. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27. (Pubitemid 36159887)
21. Green J, Berrington de Gonzalez A, Smith JS, et al.Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003; 88:1713-20. (Pubitemid 36760415)
22. Phelan DF, Gange SJ, Ahdieh-Grant L, et al. Determinants of newly detected human papillomavirus infection in HIV-infected and HIVuninfected injection drug using women. Sex Transm Dis 2009; 36:149-56.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
24. Jacobson DL, Peralta L, Farmer M, Graham NM, Gaydos C, Zenilman J. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sex Transm Dis 2000; 27:313-9. (Pubitemid 30439544)
25. Veress G, Csiky-Meszaros T, Czegledy J, Gergely L. Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results. Med Microbiol Immunol 1992; 181:181-9.
26. Rocha-Zavaleta L, Yescas G, Cruz RM, Cruz-Talonia F. Human papillomavirus infection and cervical ectopy. Int J Gynaecol Obstet 2004; 85:259-66. (Pubitemid 38622557)
27. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198:971-8.
28. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidem Biomar 2005; 14:1149-56. (Pubitemid 40656460)
29. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006; 160:151-6. (Pubitemid 43213859)
30. Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. Persistence of highrisk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 2010; 82:616-23.
31. Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009; 100:1184-90.
32. Marks MA, Gravitt PE, Burk RD, Studentsov Y, Farzadegan H, Klein SL. Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol 2010; 17:609-17.
33. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187:1246-56. (Pubitemid 36438965)